Hunsberger Holly C, Lee Seonjoo, Jin Michelle, Lanio Marcos, Whye Alicia, Cha Jiook, Scarlata Miranda, Jayaseelan Keerthana, Denny Christine A
Division of Systems Neuroscience, Research Foundation for Mental Hygiene, Inc. (RFMH) / New York State Psychiatric Institute (NYSPI), New York, NY, USA.
Center for Neurodegenerative Diseases and Therapeutics, Rosalind Franklin University of Medicine and Science/The Chicago Medical School; North Chicago, IL, USA.
bioRxiv. 2023 Jul 10:2023.07.07.548180. doi: 10.1101/2023.07.07.548180.
Neuropsychiatric symptoms (NPS), such as depression and anxiety, are observed in 90% of Alzheimer's disease (AD) patients, two-thirds of whom are women. NPS usually manifest long before AD onset creating a therapeutic opportunity. Here, we examined the impact of anxiety on AD progression and the underlying brain-wide neuronal mechanisms.
To gain mechanistic insight into how anxiety impacts AD progression, we performed a cross-sectional analysis on mood, cognition, and neural activity utilizing the ArcCreER x enhanced yellow fluorescent protein (eYFP) x APP/PS1 (AD) mice. The ADNI dataset was used to determine the impact of anxiety on AD progression in human subjects.
Female AD mice exhibited anxiety-like behavior and cognitive decline at an earlier age than control (Ctrl) mice and male mice. Brain-wide analysis of c-Fos revealed changes in regional correlations and overall network connectivity in AD mice. Sex-specific memory trace changes were observed; female AD mice exhibited impaired memory traces in dorsal CA3 (dCA3), while male AD mice exhibited impaired memory traces in the dorsal dentate gyrus (dDG). In the ADNI dataset, anxiety predicted transition to dementia. Female subjects positive for anxiety and amyloid transitioned more quickly to dementia than male subjects.
While future studies are needed to understand whether anxiety is a predictor, a neuropsychiatric biomarker, or a comorbid symptom that occurs during disease onset, these results suggest that AD network dysfunction is sexually dimorphic, and that personalized medicine may benefit male and female AD patients rather than a one size fits all approach.
神经精神症状(NPS),如抑郁和焦虑,在90%的阿尔茨海默病(AD)患者中都有观察到,其中三分之二为女性。NPS通常在AD发病前很久就出现,从而创造了一个治疗机会。在此,我们研究了焦虑对AD进展的影响以及潜在的全脑神经元机制。
为了深入了解焦虑如何影响AD进展,我们利用ArcCreER×增强型黄色荧光蛋白(eYFP)×APP/PS1(AD)小鼠对情绪、认知和神经活动进行了横断面分析。ADNI数据集用于确定焦虑对人类受试者AD进展的影响。
雌性AD小鼠比对照(Ctrl)小鼠和雄性小鼠在更早的年龄就表现出焦虑样行为和认知能力下降。对c-Fos的全脑分析揭示了AD小鼠区域相关性和整体网络连通性的变化。观察到了性别特异性的记忆痕迹变化;雌性AD小鼠在背侧CA3(dCA3)表现出记忆痕迹受损,而雄性AD小鼠在背侧齿状回(dDG)表现出记忆痕迹受损。在ADNI数据集中,焦虑预示着向痴呆症的转变。焦虑和淀粉样蛋白呈阳性的女性受试者比男性受试者更快地转变为痴呆症。
虽然需要进一步的研究来了解焦虑是预测因素、神经精神生物标志物还是疾病发作时出现的共病症状,但这些结果表明AD网络功能障碍存在性别差异,个性化医疗可能使男性和女性AD患者受益,而不是采用一刀切的方法。